Last updated: February 13, 2026
Overview of NDC 00832-1250
NDC 00832-1250 refers to Afluria, a pentavalent influenza vaccine manufactured by Seqirus. Approved for adults and children, Afluria is used for seasonal flu prevention. It is distributed mainly in the U.S. and other global markets, with specific formulations for various age groups.
Market Size and Penetration
U.S. Influenza Vaccine Market
- The influenza vaccine market was valued at approximately $4.15 billion in 2021 (Frost & Sullivan).
- The seasonal flu vaccine segment accounts for roughly 80% of this value, with a predicted CAGR of 4.5% annually from 2022 to 2027.
- Pivotal factors include vaccine availability, public immunization policies, and COVID-19's influence on vaccine infrastructure.
Afluria's Market Position
- Afluria holds a moderate market share, estimated at 8-12% of influenza vaccine sales, depending on the season.
- Primary competitors include Fluzone (Sanofi), Fluarix (GlaxoSmithKline), and Fluvirin (Seqirus).
- Market penetration constraints include patient preference, vaccine supply logistics, and vaccine efficacy perceptions.
Regulatory Status and Distribution
- In 2021, the CDC recommended flu vaccines for all persons aged 6 months and older.
- Afluria is approved via the FDA’s Biological License Application (BLA) pathway, with annual seasonal updates aligning with CDC recommendations.
- Distribution is primarily through large pharmacy chains, hospitals, and public health programs.
Pricing Analysis
Current Pricing Trends
- Average wholesale price (AWP) per dose: $25–$33 for Afluria.
- Retail prices vary by provider but generally range from $30 to $50 per dose due to markups.
- Reimbursement rates under CDC programs and private insurers typically cover the AWP plus margins, with variations.
Price Components
- Manufacturing costs are estimated to be between $2 and $4 per dose.
- Distribution, marketing, and administrative costs contribute to final prices.
- Influenza vaccine prices tend to be stable year-over-year but can fluctuate based on raw material costs.
Price Projections (2023–2027)
| Year |
Estimated Price Range per Dose |
Notes |
| 2023 |
$27–$35 |
Slight inflation driven by supply chain costs |
| 2024 |
$28–$36 |
Based on historical inflation and demand trends |
| 2025 |
$29–$37 |
Anticipated increased demand during pandemic recovery |
| 2026 |
$30–$38 |
Market stabilization expected |
| 2027 |
$31–$40 |
Potential for price increase due to raw material costs |
Market Drivers and Risks
- Drivers: Annual requirement for influenza vaccination, expanding immunization programs, and high reimbursement rates.
- Risks: Vaccine hesitancy, supply chain disruptions, competitor innovations, and regulatory alterations.
Competitive Landscape and Differentiation
Seqirus maintains its market share through:
- Expanded age indication for Afluria.
- Flexible distribution partnerships.
- Potential formulations for pediatric use, which could elevate market share.
Competitors like Sanofi's Fluzone dominate, holding approximately 60% market share in the U.S. influenza vaccine market.
Special Considerations
- The COVID-19 pandemic prompted increased influenza vaccination efforts, influencing demand projections.
- New formulations, including quadrivalent and cell-based vaccines, may impact prices and market shares.
- Government procurement policies could influence pricing and availability, especially during pandemic or supply shortages.
Key Takeaways
- The influenza vaccine market is projected to grow modestly, with Afluria maintaining a significant share.
- Current pricing ranges between $27 and $35 per dose, with slight upward pressure over the next five years.
- Market penetration is influenced by competitive products, distribution channels, and regulatory factors.
- Innovations and shifts in public health policies could alter demand patterns.
FAQs
1. How does Afluria compare price-wise to its competitors?
Afluria's average wholesale price is in line with or slightly below other leading influenza vaccines, which typically range from $25 to $40 per dose.
2. What are the main challenges for increasing Afluria’s market share?
Competitors’ established brand recognition, supply chain logistics, and vaccine efficacy concerns influence share growth.
3. How might future regulatory changes impact Afluria?
Regulations favoring enhanced vaccination coverage or new formulations could demand price adjustments or formulation updates.
4. What factors could influence influenza vaccine prices leading into 2027?
Raw material costs, manufacturing enhancements, market demand, and government procurement policies.
5. What is the expected impact of new vaccine technologies on Afluria?
Advancements like cell-based or recombinant vaccines could decrease demand for traditional egg-based vaccines, impacting pricing and sales.
Citations
- Frost & Sullivan. "U.S. Influenza Vaccine Market Report," 2022.
- CDC. "Seasonal Influenza Vaccine Effectiveness, 2021," CDC.gov.
- Seqirus. "Afluria Product Information," 2023.
- IQVIA. "Vaccine Market Data," 2022.
- Bloomberg Intelligence. "Pharmaceutical Pricing Trends," 2023.
